Acadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Nuplazid (pimavanserin) for use in dementia-related psychosis (DRP ...

previously undiagnosed 'AIDS dementia complex', delirium, medication-induced psychosis, and 'primary HIV psychosis'. New-onset psychosis in HIV-seropositive patients has prevalence estimates ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

Usually the substance-induced psychotic episode is relatively ... As in adults, delirium and dementia can mimic psychotic phenomena. Fortunately, dementia is very rare in this age group, and ...

Emil Kraepelin, the founder of modern scientific psychiatry, who believed the chief origin of psychiatric disease to be biological and genetic malfunction, described schizophrenia as dementia ...

Depression, anxiety, and other neuropsychiatric symptoms (NPS) are more common in older adults with visual impairment and vision loss. In this study, researchers assessed the associations between ...

People with Parkinson's disease (PD) who experience visual hallucinations have reduced brain responses to unexpected visual changes, a marker known as visual mismatch negativity (vMMN).

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...

Unlike other antipsychotics that treat schizophrenia, the agency approved Cobenfy without a “black box” warning on the ...

For over 60 years, the dopaminergic hypothesis of schizophrenia has formed the basis of the schizophrenia treatment paradigm.

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...